One example are the DETECT-III trials, the first randomized interventional study indicating clinical utility of CTC characterization that revealed that breast cancer patients with HER2 negative tumors have HER2 positive CTCs in the circulation. The gene discussed is ERBB2; the disease is breast cancer.